Literature DB >> 32101633

The role of anti-flavivirus humoral immune response in protection and pathogenesis.

Arianna Mahely Hurtado-Monzón1, Carlos Daniel Cordero-Rivera1, Carlos Noe Farfan-Morales1, Juan Fidel Osuna-Ramos1, Luis Adrián De Jesús-González1, José Manuel Reyes-Ruiz1, Rosa María Del Ángel1.   

Abstract

Flavivirus infections are a public health threat in the world that requires the development of safe and effective vaccines. Therefore, the understanding of the anti-flavivirus humoral immune response is fundamental to future studies on flavivirus pathogenesis and the design of anti-flavivirus therapeutics. This review aims to provide an overview of the current understanding of the function and involvement of flavivirus proteins in the humoral immune response as well as the ability of the anti-envelope (anti-E) antibodies to interfere (neutralizing antibodies) or not (non-neutralizing antibodies) with viral infection, and how they can, in some circumstances enhance dengue virus infection on Fc gamma receptor (FcγR) bearing cells through a mechanism known as antibody-dependent enhancement (ADE). Thus, the dual role of the antibodies against E protein poses a formidable challenge for vaccine development. Also, we discuss the roles of antibody binding stoichiometry (the concentration, affinity, or epitope recognition) in the neutralization of flaviviruses and the "breathing" of flavivirus virions in the humoral immune response. Finally, the relevance of some specific antibodies in the design and improvement of effective vaccines is addressed.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ADE; Zika; antibodies; dengue; pathogenesis; protection

Year:  2020        PMID: 32101633     DOI: 10.1002/rmv.2100

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  12 in total

1.  A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice.

Authors:  Ryan J Malonis; George I Georgiev; Denise Haslwanter; Laura A VanBlargan; Georgia Fallon; Olivia Vergnolle; Sean M Cahill; Richard Harris; David Cowburn; Kartik Chandran; Michael S Diamond; Jonathan R Lai
Journal:  PLoS Pathog       Date:  2022-06-09       Impact factor: 7.464

2.  Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.

Authors:  P J Klasse; John P Moore
Journal:  Elife       Date:  2020-06-23       Impact factor: 8.140

Review 3.  The Regulation of Flavivirus Infection by Hijacking Exosome-Mediated Cell-Cell Communication: New Insights on Virus-Host Interactions.

Authors:  José Manuel Reyes-Ruiz; Juan Fidel Osuna-Ramos; Luis Adrián De Jesús-González; Selvin Noé Palacios-Rápalo; Carlos Daniel Cordero-Rivera; Carlos Noe Farfan-Morales; Arianna Mahely Hurtado-Monzón; Carla Elizabeth Gallardo-Flores; Sofía L Alcaraz-Estrada; Juan Santiago Salas-Benito; Rosa María Del Ángel
Journal:  Viruses       Date:  2020-07-16       Impact factor: 5.048

Review 4.  Zika Virus Pathogenesis: A Battle for Immune Evasion.

Authors:  Judith Estévez-Herrera; Silvia Pérez-Yanes; Romina Cabrera-Rodríguez; Daniel Márquez-Arce; Rodrigo Trujillo-González; José-David Machado; Ricardo Madrid; Agustín Valenzuela-Fernández
Journal:  Vaccines (Basel)       Date:  2021-03-22

Review 5.  The Nuclear Pore Complex Is a Key Target of Viral Proteases to Promote Viral Replication.

Authors:  Luis Adrián De Jesús-González; Selvin Palacios-Rápalo; José Manuel Reyes-Ruiz; Juan Fidel Osuna-Ramos; Carlos Daniel Cordero-Rivera; Carlos Noé Farfan-Morales; Ana Lorena Gutiérrez-Escolano; Rosa María Del Ángel
Journal:  Viruses       Date:  2021-04-19       Impact factor: 5.048

6.  A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus.

Authors:  Bharti Bhatia; Kimberly Meade-White; Elaine Haddock; Friederike Feldmann; Andrea Marzi; Heinz Feldmann
Journal:  NPJ Vaccines       Date:  2021-12-14       Impact factor: 7.344

7.  Antibody-dependent enhancement representing in vitro infective progeny virus titer correlates with the viremia level in dengue patients.

Authors:  Atsushi Yamanaka; Hisham Ahmed Imad; Weerapong Phumratanaprapin; Juthamas Phadungsombat; Eiji Konishi; Tatsuo Shioda
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

8.  The Nuclear Pore Complex: A Target for NS3 Protease of Dengue and Zika Viruses.

Authors:  Luis Adrián De Jesús-González; Margot Cervantes-Salazar; José Manuel Reyes-Ruiz; Juan Fidel Osuna-Ramos; Carlos Noe Farfán-Morales; Selvin Noé Palacios-Rápalo; José Humberto Pérez-Olais; Carlos Daniel Cordero-Rivera; Arianna M Hurtado-Monzón; Fernando Ruíz-Jiménez; Ana Lorena Gutiérrez-Escolano; Rosa María Del Ángel
Journal:  Viruses       Date:  2020-05-26       Impact factor: 5.048

9.  Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara.

Authors:  Nereida Jiménez de Oya; Patricia Pérez; Ana-Belén Blázquez; Estela Escribano-Romero; Mariano Esteban; Juan-Carlos Saiz; Juan García-Arriaza; Miguel A Martín-Acebes
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-15

Review 10.  The key amino acids of E protein involved in early flavivirus infection: viral entry.

Authors:  Tao Hu; Zhen Wu; Shaoxiong Wu; Shun Chen; Anchun Cheng
Journal:  Virol J       Date:  2021-07-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.